Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Several other equities analysts have also recently weighed in on the company. Piper Sandler restated an overweight rating and issued a $5.00 price objective on shares of Aptose Biosciences in a report on Wednesday, April 3rd. Canaccord Genuity Group decreased their price objective on Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 16th. Finally, HC Wainwright restated a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a report on Friday, June 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $14.83.

Aptose Biosciences Trading Up 1.2 %

APTO stock opened at $0.76 on Friday. The stock has a 50-day moving average price of $1.05 and a two-hundred day moving average price of $1.60. The stock has a market cap of $13.74 million, a PE ratio of -0.12 and a beta of 1.39. Aptose Biosciences has a 1 year low of $0.71 and a 1 year high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. On average, analysts forecast that Aptose Biosciences will post -2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.